AR103782A1 - ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN - Google Patents
ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHNInfo
- Publication number
- AR103782A1 AR103782A1 ARP160100498A ARP160100498A AR103782A1 AR 103782 A1 AR103782 A1 AR 103782A1 AR P160100498 A ARP160100498 A AR P160100498A AR P160100498 A ARP160100498 A AR P160100498A AR 103782 A1 AR103782 A1 AR 103782A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- antagonists
- disease
- integrin
- crohn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan métodos de tratamiento de trastornos inflamatorios gastrointestinales tales como enfermedades intestinales inflamatorias que incluyen enfermedad de Crohn. También se proporcionan métodos de administración y dosificación de antagonistas de integrina b7, tales como anticuerpos anti-integrina b7. Además, se proporcionan métodos de administración y dosificación de tales antagonistas de integrina b7 para inducir la remisión o para inducir remisión y mantener la remisión de la enfermedad de Crohn. Reivindicación 2: El método de acuerdo con la reivindicación 1, en donde el antagonista de integrina b7 es un anticuerpo monoclonal de anti-integrina b7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562121290P | 2015-02-26 | 2015-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103782A1 true AR103782A1 (es) | 2017-05-31 |
Family
ID=55487172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100498A AR103782A1 (es) | 2015-02-26 | 2016-02-25 | ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN |
Country Status (12)
Country | Link |
---|---|
US (3) | US20180086833A1 (es) |
EP (2) | EP3978530A1 (es) |
JP (2) | JP2018507868A (es) |
KR (1) | KR20170120601A (es) |
CN (2) | CN113209289A (es) |
AR (1) | AR103782A1 (es) |
AU (2) | AU2016222683A1 (es) |
CA (1) | CA2972099A1 (es) |
HK (1) | HK1244229A1 (es) |
IL (1) | IL253130B2 (es) |
MX (1) | MX2017010336A (es) |
WO (1) | WO2016138207A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103649336A (zh) | 2011-05-10 | 2014-03-19 | 雀巢产品技术援助有限公司 | 用于个体化治疗管理的疾病活动性表征方法 |
WO2018111322A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of integrin inhibitors at the site of gastrointestinal tract disease |
WO2018200818A2 (en) * | 2017-04-28 | 2018-11-01 | Millennium Pharmaceuticals, Inc. | Method of treating pediatric disorders |
CA3064529C (en) | 2017-05-31 | 2021-12-14 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in crohn's disease patients |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
TW202003466A (zh) | 2018-04-12 | 2020-01-16 | 美商莫菲克醫療股份有限公司 | 人類整合素α4β7拮抗劑 |
US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
EP3810268A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2020117795A1 (en) * | 2018-12-04 | 2020-06-11 | Prometheus Biosciences, Inc. | Assessment and monitoring of mucosal healing in children and adults with crohn's disease |
UY38926A (es) | 2019-10-16 | 2021-05-31 | Morphic Therapeutic Inc | INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA |
CA3190109A1 (en) * | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
WO2023061502A1 (zh) * | 2021-10-15 | 2023-04-20 | 苏州生物医药转化工程中心 | 一种双特异性结合分子 |
TW202330613A (zh) * | 2021-11-12 | 2023-08-01 | 美商建南德克公司 | 使用整聯蛋白β7拮抗劑治療克隆氏病之方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4256833A (en) | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
CA2046909A1 (en) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
AU652540B2 (en) | 1989-07-19 | 1994-09-01 | Xoma Corporation | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6551593B1 (en) * | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1485127E (pt) * | 2002-02-25 | 2011-09-07 | Elan Pharm Inc | Administração de agentes para o tratamento de inflamação |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2555355T3 (es) * | 2004-09-03 | 2015-12-30 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
ES2533480T3 (es) * | 2008-05-16 | 2015-04-10 | F. Hoffmann-La Roche Ag | Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7 |
AU2012236304C1 (en) * | 2011-03-31 | 2017-01-05 | Genentech, Inc. | Methods of administering beta7 integrin antagonists |
BR112015007528A2 (pt) * | 2012-10-05 | 2018-09-04 | Genentech Inc | método para prever a resposta, para prever a responsividade, para identificar e para tratar um paciente que tem uma disfunção inflamatória gastrointestinal. |
KR20150128859A (ko) * | 2013-03-15 | 2015-11-18 | 암젠 인크 | 항-il23 항체를 사용하여 크론병을 치료하는 방법 |
BR112015024856A2 (pt) * | 2013-03-27 | 2018-04-17 | Genentech Inc | métodos de determinação ou de monitoramento |
AR099856A1 (es) * | 2014-03-27 | 2016-08-24 | Genentech Inc | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado |
-
2016
- 2016-02-25 EP EP21184652.2A patent/EP3978530A1/en active Pending
- 2016-02-25 AU AU2016222683A patent/AU2016222683A1/en not_active Abandoned
- 2016-02-25 AR ARP160100498A patent/AR103782A1/es unknown
- 2016-02-25 MX MX2017010336A patent/MX2017010336A/es unknown
- 2016-02-25 WO PCT/US2016/019468 patent/WO2016138207A1/en active Application Filing
- 2016-02-25 EP EP16708894.7A patent/EP3262072A1/en not_active Withdrawn
- 2016-02-25 CN CN202110281006.0A patent/CN113209289A/zh active Pending
- 2016-02-25 CA CA2972099A patent/CA2972099A1/en active Pending
- 2016-02-25 CN CN201680012164.3A patent/CN107257693A/zh active Pending
- 2016-02-25 KR KR1020177023210A patent/KR20170120601A/ko not_active Application Discontinuation
- 2016-02-25 JP JP2017545295A patent/JP2018507868A/ja active Pending
-
2017
- 2017-06-22 IL IL253130A patent/IL253130B2/en unknown
- 2017-08-21 US US15/681,881 patent/US20180086833A1/en not_active Abandoned
-
2018
- 2018-03-19 HK HK18103814.8A patent/HK1244229A1/zh unknown
-
2020
- 2020-02-19 US US16/795,296 patent/US20200392232A1/en not_active Abandoned
-
2021
- 2021-11-24 AU AU2021273587A patent/AU2021273587A1/en active Pending
-
2022
- 2022-01-21 JP JP2022007509A patent/JP2022064930A/ja active Pending
- 2022-02-03 US US17/592,227 patent/US20220403034A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20170120601A (ko) | 2017-10-31 |
JP2018507868A (ja) | 2018-03-22 |
WO2016138207A1 (en) | 2016-09-01 |
CA2972099A1 (en) | 2016-09-01 |
IL253130A0 (en) | 2017-08-31 |
US20200392232A1 (en) | 2020-12-17 |
HK1244229A1 (zh) | 2018-08-03 |
IL253130B1 (en) | 2023-03-01 |
CN107257693A (zh) | 2017-10-17 |
EP3262072A1 (en) | 2018-01-03 |
MX2017010336A (es) | 2017-12-20 |
EP3978530A1 (en) | 2022-04-06 |
CN113209289A (zh) | 2021-08-06 |
JP2022064930A (ja) | 2022-04-26 |
AU2021273587A1 (en) | 2021-12-16 |
IL253130B2 (en) | 2023-07-01 |
AU2016222683A1 (en) | 2017-07-13 |
US20180086833A1 (en) | 2018-03-29 |
US20220403034A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103782A1 (es) | ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
MX2022010809A (es) | Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales. | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
AR092908A1 (es) | Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria | |
MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
BR112016013109A2 (pt) | anticorpos de anti-siglec-8 e métodos de seu uso | |
EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
BR112015026122A2 (pt) | métodos para usar interleucina-10 para tratar doenças e desordens | |
EA201500364A1 (ru) | Лечение глазных заболеваний | |
EA201591825A1 (ru) | Антагонизм миостатина у субъектов - людей | |
AU2016204185A1 (en) | Methods of administering beta7 integrin antagonists | |
EA201691836A1 (ru) | Антитела к mcam и соответствующие способы их применения | |
EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
MA40592A (fr) | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 | |
EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
MX2016013611A (es) | Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |